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Angiotensin II (Ang II) exerts an acute bimodal effect on proximal tubule NHE3: while low doses stimu-
late the exchanger, high doses inhibit it. In the present study, we have investigated the chronic effects of
Ang II on NHE3 expression and transcriptional regulation. Treatment of a tubular epithelial cell line, OKP,
with Ang II 1011 M signiﬁcantly increased NHE protein expression and mRNA levels, without evidence of
bimodal effect. No change in mRNA half-life was detected, but transient transfection studies showed a
signiﬁcant increase in NHE3 promoter activity. Binding sites for Sp1/Egr-1 and AP2 transcription factors
of the NHE3 proximal promoter were mutated and we observed that the Sp1/Egr-1 binding site integrity
is necessary for Ang II stimulatory effects. Inhibition of cytochrome P450, PI3K, PKA and MAPK pathways
prevented the Ang II stimulatory effect on the NHE3 promoter activity. Taking all the results together, our
data reveal that chronic Ang II treatment exerts a stimulatory effect on NHE3 expression and promoter
activity. The Ang II up-regulation of the NHE3 promoter activity appears to involve the Sp1/Egr-1 binding
site and the interplay of several intracellular signaling pathways.
 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
The renin angiotensin aldosterone system (RAAS) is critically in-
volved in regulation of blood pressure and ﬂuid balance. Angioten-
sin II (Ang II) is the primary effector of a variety of RAAS-induced
physiological actions, for instance, induces aldosterone secretion,
acts as a potent vasoconstrictor peptide, and has important effects
on ﬂuid reabsorption [1]. Previous studies have shown that Ang II
can directly modulate NHE3 expression and activity [2,3] along the
proximal tubules, where this protein plays a key role in reabsorp-
tion of electrolyte and water [4].
Ang II exerts an acute biphasic effect on NHE3 activity. Low con-
centrations of the hormone stimulate the exchanger whereas high
concentrations inhibit it [5,6]. This acute effect is mediated by AT1
receptor (AT1R), a G protein coupled receptor whose activation is
responsible for most of the Ang II actions [7,8]. Activation of c-Src
and PI3 kinases are involved in the acute stimulatory effects [9,2]
and the cytochrome P-450 pathway seems to be involved in both,
the stimulatory as well as the inhibitory effects [10,11]. Chronic
Ang II treatment increases NHE3 protein and mRNA levels [11,12],
besides inducing promoter activation [12]. The chronic Ang II-
dependent changes in NHE3 activity and expression are dependentPhysiology and Biophysics,
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lsevier OA license.on AT1R activation [11], however, the AT1R involvement in pro-
moter response is unknown. It would be of great interest to identify
the signaling pathways and the regulatory elements involved in the
chronic Ang II effects on NHE3 transcriptional modulation.
Several studies have demonstrated the role of promoter activa-
tion in NHE3 regulation by multiple stimuli [13–15]. Some relevant
elements that modulate NHE3 gene transcription were mapped to
the proximal promoter, where the transcription factors Sp1/Sp3
and Egr-1 can compete for neighboring binding sites [16,17]. Our
main goal in the present study was to investigate the chronic ef-
fects of Ang II on NHE3 activity, expression and transcriptional
modulation. Our ﬁndings conﬁrmed that chronic Ang II promotes
critical changes in NHE3 activity, protein and mRNA abundance,
and transcriptional pattern of expression. We have identiﬁed one
Sp1/Egr-1 binding site in NHE3 proximal promoter as a relevant
element for Ang II transcriptional activation and observed that sev-
eral intracellular signaling pathways may play a role in this pro-
moter response.
2. Materials and methods
2.1. Reagents
OKP cells were provided by Dr. O.W. Moe (University of Texas
Southwestern Medical Center, Dallas, TX). Dulbecco’s modiﬁed
Eagle’s medium (DMEM), heat-inactivated fetal bovine serum,
sodium pyruvate, and penicillin–streptomycin were purchased
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from Molecular Probes (Eugene, OR). The monoclonal (MAb) anti-
NHE3 antibody 3H3 was kindly provided by Dr. Peter Aronson
and Dr. Daniel Biemesderfer at Yale University. The monoclonal
antibody anti-actin (JLA20) was obtained from Calbiochem (San
Diego, CA); Goat anti-mouse secondary antibody from Zymed
(San Francisco, CA); Lipofectamine Plus Reagent and Platinum
Taq DNA Polymerase from Invitrogen (Carlsbad, CA); Dual Lucifer-
ase Assay System, pGL3-Basic vector and pRL-CMV vector from
Promega (Madison, WI); SYBR GREEN-PCR Core Reagents and other
reagents employed for real-time PCR from Applied Biosystems
(Foster City, CA). All other reagents and chemicals were obtained
from Sigma (St. Louis, MO), unless otherwise speciﬁed.2.2. Cell culture
OKP cells were maintained as previously described [13]. For
experiments, cells were seeded onto tissue culture plates, grown
to conﬂuence, and serum starved for 48 h before studies. When
indicated, Ang II was added to the culture medium 24 h before pro-
cedures. In order to inhibit Ang II receptors (AT1R), losartan 105 M
was added 5 min before adding Ang II.2.3. SDS–PAGE and immunoblotting
Total cell extracts were prepared from OKP cells as described
elsewhere [18]. The antibody dilutions used were 1:100 (anti-
NHE3) and 1:10,000 (anti-actin).2.4. Fluorescence microscopy measurement of pHi and cell pH recovery
NHE3 activity was measured in OKP cells grown on glass slides
using the NH4Cl pulse technique and the ﬂuorescent pH-sensitive
probe, BCECF, as previously detailed [19]. To identify the mecha-
nisms responsible for proton transport, after the NH4Cl pulse, we
bathed the cells either with control solution (vehicle, DMSO
1:5000); or solution containing baﬁlomycin 0.1 lM (inhibitor of
V-type H+ ATPase); or HOE 694 20 lM (inhibitor of NHE1 and 2);
or S3226 100 lM (inhibitor of NHE3); or NMDG solution (NMDG,
N-methyl-D-glucamine, substituting Na+ in Na+-free solution).2.5. RNA extraction and real time quantitative RT-PCR
Total RNA extraction, reverse transcription and real time poly-
merase chain reactions were performed as described [13], except
for the Actinomycin D (Act D) experiments, in which the control
gene 18S ribosomal RNA was used to normalize the results. Oligo-
nucleotide primers used for 18S were, 50-ACGGCCGGTACAGTGAA-
ACT-30 (forward) and 50-CGGGTTGGTTTTGGTCTGAT-30 (reverse).2.6. Construction of reporter plasmid
Generation of the recombinant vectors containing the Fireﬂy
luciferase gene controlled by the NHE3 gene promoter was de-
scribed previously [13]. We have analyzed three fragments of
the promoter cloned into the pGL3-basic vector (152/
+55, 85/+31; 65/+31). In order to verify the involvement of
Sp1/Egr-1 and AP2 transcription factors in the stimulatory effect
of Ang II on NHE3 promoter activity, two site directed mutations
in a proximal region of the promoter (60/+31) were performed.
Two adenines substituted one cytosine and one guanine in the
Sp1/Egr-1 binding site (nucleotides 58 and 59) and two ade-
nines substituted one guanine and one cytosine in the AP2 bind-
ing site (nucleotides 51 and 52).2.7. Luciferase reporter gene assay
The transient transfection of OKP cells were performed as de-
scribed elsewhere [13]. After incubation for 4 h in transfection
medium, cells were serum starved for 48 h and then treated with
Ang II for 24 h. Luciferase was analyzed using the Dual-Luciferase
Reporter Assay System.
2.8. Statistical analysis
Values are presented as means ± SE. Statistical signiﬁcance was
determined by ANOVA followed by Tukey’s post hoc test. Student
t-test was used when indicated. P value <0.05 was considered sta-
tistically signiﬁcant.3. Results
3.1. Effects of chronic Ang II on NHE3 activity
In order to determine the contribution of NHE isoforms and of
V-type – H+ ATPase in H+ extrusion, pHi recovery from an acid
load in OKP cells was evaluated by the NH4Cl pulse technique
in the presence of speciﬁc transporter inhibitors. Care was taken
to maintain the same level of acidiﬁcation after ammonium pulse
in all studied groups. The experiments were performed in the
presence of vehicle, or baﬁlomycin (inhibitor of V-type H+ ATP-
ase); or HOE 694 (inhibitor of NHE1 and 2); or S3226 (inhibitor
of NHE3); or NMDG solution (Na+ free solution). The pHi recovery
was reduced by approximately 77% in the presence of S3226 and
there was no pHi recovery in absence of extracellular Na+
(Fig. 1A).
OKP cells were incubated with different concentrations of Ang II
(107–1012 M) for 24 h in order to verify the existence of a bipha-
sic regulation in chronic treatments, as well as during acute regu-
lation. There was an increase in the rate of pHi recovery of
approximately 64% when cells were treated with 1011 M Ang II,
as depicted in Fig. 1B, and other concentrations had no signiﬁcant
effect. None of the evaluated concentrations was able to inhibit
NHE3 activity. Pre-treatment of cells with losartan before incuba-
tion with Ang II for 24 h completely abolished the stimulatory ef-
fect of Ang II on NHE3 activity (Fig. 1C).
3.2. Effects of chronic Ang II on NHE3 expression
Different regulatory mechanisms can lead to changes is NHE3
activity. Western blot experiments were performed to verify if
chronic Ang II exposure led to an increase in total NHE3 expression.
As shown in (Fig. 2A), 24 h Ang II treatment is associated with a
signiﬁcant increase in the level of NHE3 protein in treated cells.
This increase was completely abolished in cells pretreated with
losartan (Fig. 2B).
To demonstrate a relationship between NHE3 protein and
mRNA levels, cells were exposed to Ang II for 24 h and NHE3
mRNA expression was evaluated by real time PCR. Ang II pro-
longed treatment led to an increase in approximately 42% in
NHE3 mRNA levels and pretreatment with losartan completely
abolished this up-regulation (Fig. 2C). To assure that the ob-
served increase in NHE3 mRNA levels was not due to changes
in NHE3 mRNA half-life, the NHE3 mRNA stability was evaluated
by using Act D 5 lg/ml to stop new transcriptions. Remnant lev-
els of NHE3 mRNA were measured 3, 6, 9, 12, and 24 h after Act
D addition to the culture media and NHE3 mRNA was assessed
by real time PCR. As shown in Fig. 2D, there was no signiﬁcant
change in mRNA half-life in cells treated and not treated with
Ang II.
Fig. 1. Experiments of pHi recovery after NH4Cl pulse. The initial rates of pHi recovery were calculated from the presented curves by linear regression analysis. (A) Effects of
baﬁlomycin (V-type H+ ATPase inhibitor); HOE 694 (NHE1 and 2 inhibitor); S3226 (NHE3 inhibitor) and absence of extracellular Na+ on pHi recovery rate (NMDG = 0 Na+
solution). P < 0.001. (B) Dose-dependent effect of prolonged Ang II treatment on NHE3 activity. P < 0.01 compared to control group. (C) Effect of losartan pretreatment
followed by Ang II 1011 M for 24 h on NHE3 activity. P < 0.001 compared to control group and P < 0.01 compared to losartan and Ang II 1011 M + losartan groups.
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To further investigate the transcriptional involvement in Ang II
chronic effects, we analyzed the NHE3 promoter activity. Three
fragments of NHE3 promoter, 152/+55, 85/+31 and 65/+31,
were transiently transfected into OKP cells and reporter gene
activity was analyzed in the presence of Ang II for 24 h. As de-
picted in Fig. 3A, the NHE3 promoter activity of the 65/+31 frag-
ment was signiﬁcantly increased in cells treated with Ang II for
24 h, suggesting that the transcriptional regulation is involved
in the chronic stimulatory effect of Ang II on NHE3. This stimula-
tory effect was completely abolished in cells pretreated with
losartan (Fig. 3B). Attempting to investigate the transcription fac-
tor involved in Ang II-dependent stimulation of NHE3 promoter
activity, we performed site directed mutagenesis on the consen-
sus binding sites for the transcription factors Sp1/Egr-1 and AP2
identiﬁed in the segment 65/+31 of the NHE3 promoter.
Fig. 3C shows the scheme of the mutated fragments. These frag-
ments were transiently transfected into OKP cells and reporter
gene activity was analyzed in the presence of Ang II for 24 h.
As shown in Fig. 3D, the Sp1/Egr-1 binding site mutation com-
pletely abolished the stimulatory effect, while the AP2 binding
site mutation only partially prevented this effect, suggesting thatthe Sp1/Egr-1 binding site is directly involved in Ang II stimula-
tory effect on NHE3 promoter activity.
3.4. Signaling pathways involved in chronic Ang II-dependent NHE3
stimulatory promoter activity
In order to investigate the mechanism of action involved in
modulation of the transcription, we used a panel of inhibitors for
pathways known to be activated by Ang II. OKP cells were transfec-
ted with the 65/+31 promoter segment and pretreated for one
hour with speciﬁc inhibitors, followed by 24 h Ang II incubation.
The ﬁrst set of inhibitors were: ketoconazole, a cytochrome P450
inhibitor which blocks fatty acid epoxygenation; U73122, a phos-
pholipase C inhibitor; KT5720, a PKA inhibitor and wortmannin,
a PI3-K inhibitor (Fig. 4A). The MAPK cascade was also inhibited
using tyrphostin AG-1478, an EGF receptor tyrosine kinase inhibi-
tor; PD98059, a MAPKK inhibitor and SB203580, a p38 MAPK
inhibitor (Fig. 4B). Another set of experiments was performed
using inhibitors of the JAK/STAT pathway: 1,2,3,4,5,6-hexabromo-
cyclohexane, a JAK2 autophosphorilation inhibitor and Cucurbita-
cin I, a JAK2/STAT3 inhibitor (Fig. 4C). The presence of the
inhibitors in absence of Ang II did not exert any effect on 65/
+31 promoter activity, except for SB203580, that signiﬁcantly
Fig. 2. Effects of chronic Ang II treatment on NHE3 expression and mRNA levels. (A) Effects of Ang II 1011 M for 24 h on NHE3 protein levels evaluated by Western blot. The
blot was re-probed with actin antibody. P = 0.0076, as determined by Student’s t-test. (B) Effect of losartan pretreatment followed by Ang II 1011 M for 24 h on NHE3
protein levels evaluated by Western blot. The blot was re-probed with actin antibody. P < 0.05 compared to control and 1011 M + losartan groups. (C) Total RNA was
extracted and subjected to real time RT-PCR. P < 0.05 compared to control and losartan groups; P < 0.01 compared to 1011 M + losartan. (D) Total RNA was obtained at time
0, 3, 6, 9, 12, and 24 h after inhibition of transcription by actinomycin D (Act D) 5 lg/ml in the presence or absence of Ang II 1011 M and subjected to real time RT-PCR. Data
are presented as% of maximum normalized by 18 S expression. Superior right: 18 S time-dependent expression during Act D treatment in the presence or absence of Ang II.
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U73122; tyrphostin AG-1478; 1,2,3,4,5,6-hexabromocyclohexane
and Cucurbitacin I completely abolished the Ang II stimulatory ef-
fect on NHE3 promoter activity and only U73122 partially blocked
the Ang II-dependent NHE3 promoter stimulation.
4. Discussion
As previously observed by Amemyia and co-workers [20], our
results show that NHE3 is the major Na+/H+ exchanger functionally
expressed in OKP cells. We still observed a small Na+ dependent
pHi recovery in the presence of a NHE3 inhibitor, which was com-
pletely abolished in a Na+ free solution. Since NHE1 and NHE2
inhibitors did not change the pHi recovery rate, the remaining
pHi recovery in the presence of S3226 may be due to incomplete
inhibition of NHE3.
Our results showed that Ang II chronic exposure leads to direct
effects on NHE3 activity and expression, which is consistent with
previous studies [3]. We demonstrated that chronic 1011 M Ang
II treatment signiﬁcantly stimulates NHE3 activity. This low dose
is known to activate NHE3 under acute treatment, suggesting thatthe chronic effects could preserve some link with the early events
triggered by acute AT1R activation. All the higher concentrations
have no signiﬁcant effect on NHE3 activity, suggesting that the bi-
phasic effect observed in acute Ang II treatment is not observed in
prolonged exposure. Recently, Xu et al. [12] observed chronic Ang
II-dependent NHE3 activation in OKP cells only in a dose of 107 M.
Although our observations agree on the absence of a biphasic ef-
fect, ours results disagree about the dose that chronically activates
NHE3. This discrepancy might be attributed to different batches of
OKP cells or, less probable, to differences in the exposure time to
Ang II, 16 h versus 24 h.
In addition to the observed increase in NHE3 activity, we also
demonstrated a signiﬁcant increase in NHE3 protein and NHE3
transcript abundance in OKP cells treated with Ang II 1011 M
for 24 h. To evaluate whether the higher level of NHE3 mRNA
was due to changes in transcript stability, we evaluated the
inﬂuence of Ang II on the NHE3 message half-life. We found that
NHE3 mRNA half-life was not signiﬁcantly different in cells trea-
ted or not with Ang II, suggesting that the higher NHE3 tran-
script levels observed was due to increase in NHE3 new
transcripts.
Fig. 3. Effects of chronic Ang II on the NHE3 promoter activity. (A) Fireﬂy luciferase reporter constructs containing the NHE3 promoter segment 152/+55, 85/+31 and 65/
+31 or no fragment of NHE3 promoter (basic) were generated and cotransfected into OKP cells along with the pRL-CMV plasmid, which provides constitutive expression of
Renilla luciferase. Cells were harvested after 24 h of treatment with 10–11 M Ang II and Fireﬂy and Renilla luciferase activity was measured. P < 0.0001 as determined by
Student’s t-test. (B) Cells were cotransfected with NHE3 promoter fragment 65/+31 and pRL-CMV plasmid, pretreated with losartan and treated with 1011 M Ang II for 24 h.
P < 0.05 compared to control group; P < 0.001 compared to losartan and 1011 M Ang II + losartan groups. (C) Original nucleotide sequence of the 60/+31 rat NHE3
promoter region and substitute nucleotides (bold/italic) in site directed mutation constructs. The transcription start site is marked +1. (D) Cells were cotransfected with the
original sequence or site directed mutations 60/+31 of rat NHE3 promoter and pRL-CMV plasmid and treated with 1011 M Ang II for 24 h. P < 0.05 compared to control and
Sp1/Egr-1 groups; P < 0.01 and P < 0.001 compared to control and Sp1/Egr-1 groups.
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onstrated that chronic Ang II induces NHE3 promoter activation,
in OKP cells transfected with constructs encompassing 1360 and
548 bp of 50 FS of the rat NHE3 gene [12], and in Caco-2BBE cells,
transfected with constructs spanning 2200 bp of the 50FS [11]. As
we have previously observed that the promoter constructs shorter
than 150 bp of the 50FS exhibit the highest activities [13], we fo-
cused our analysis on the proximal promoter, a region already
known to be responsive to other stimuli [16,17]. By 50-deletion
analyses of the NHE3 promoter–reporter constructs, we localized
another Ang II responsive region to the sequence spanning 65/
+31 bp, in addition to the previously described responsive ele-
ments in the region spanning 548/149 [12]. Ang II also modu-
lates the cyclin D1 gene by increasing the activity of its proximal
promoter through mediation of Erg-1 transcription factor, which
binds to the consensus sequence CCGCCC localized in the 136
to 96 bp of cyclin D1 promoter region [21]. We searched for thismotif in the proximal rat NHE3 promoter and we found an identi-
cal sequence in the region 60 to 55, which is part of the 65/
+31 fragment, the Ang II responsive region demonstrated in the
present study. Site directed mutations were performed to investi-
gate the involvement of Sp1/Egr-1 and AP2 transcription factors
in the Ang II response and our results suggest that the Sp1/Egr-1
binding site integrity is necessary for the observed Ang II stimula-
tory effect. Sp1/Egr-1 binding sites are related with the inhibition
of NHE3 promoter activity by IFN-c, TNF-a and serotonin [17,22]
and its stimulation by PMA and sodium butyrate [16,15]. All the
chronic effects of Ang II on NHE3 were completely abolished in
cells pretreated with losartan before adding Ang II 1011 M for
24 h. Thus, our results strongly support the AT1R as the mediator
of the chronic Ang II NHE3 stimulation. AT1R activation can un-
leash complex signal transduction that involves multiple intracel-
lular pathways. The cytochrome P-450-dependent metabolites of
arachidonate seem to be involved in the acute inhibitory, as well
Fig. 4. Effects of intracellular signaling pathway inhibitors on the Ang II-mediated up-regulation of the NHE3 promoter activity. (A) Cells were cotransfected with NHE3
promoter fragment 65/+31 and pRL-CMV plasmid, pretreated for 1 h with ketoconazole (cytochrome P450 inhibitor), U73122 (PLC inhibitor), wortmannin (PI3 K inhibitor)
and KT5720 (PKA inhibitor) followed by 1011 M Ang II treatment for 24 h or not (control). P < 0.05 compared to control group; P < 0.01 and P < 0.001 compared to Ang II
group. (B) Cells were cotransfected with NHE3 promoter fragment 65/+31 and pRL-CMV plasmid, pretreated for 1 h with tyrphostin AG-1478 (EGFR inhibitor); PD98059
(MAPKK inhibitor) and SB203580 (MAPK inhibitor) followed by 1011 M Ang II treatment for 24 h or not (control). P < 0.05 compared to control group and PD98059 group;
P < 0.01 compared to Ang II group. (C) Cells were cotransfected with NHE3 promoter fragment 65/+31 and pRL-CMV plasmid, pretreated for 1 h with
hexabromocyclohexane (JAK2 autophosphorilation inhibitor) and cucurbitacin I (JAK2/STAT3 inhibitor) followed by 1011 M Ang II treatment for 24 h or not (control).
P < 0.05 and P < 0.01 compared to control group.
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sults demonstrate that this signaling pathway is also involved in
the chronic stimulatory effect of Ang II on NHE3 promoter activity.
Although acute generation of cAMP is frequently associated to re-
duced NHE3 activity, persistent increase in cAMP was previously
demonstrated to up-regulate NHE3 [22]. Our present results
showed that the PKA signaling pathway is necessary for Ang II
transcription activation of the NHE3 proximal promoter. The
responsive Ang II site identiﬁed here does not possess a CRE bind-
ing element, suggesting that transcription dependence on cAMP
occurs through PKA phosphorylation of transcription factors, as de-
scribed for cAMP-induced transcription of the CYP11A gene [23].
Sp1 might be the phosphorylation target. Our data indicate that
PI3 K and MAPK were also involved in the Ang II stimulatory effect.
Interestingly, the EGFR do not seem to be involved in the Ang II
stimulatory effect, whereas the MAPKK certainly participates.
These results suggest transactivation of the MAPK pathway. Since
PI3 K was earlier described as responsible for the transactivationof MAPKK [24], we can speculate that this type of crosstalk could
occur in our experimental model.
In conclusion, transcriptional up-regulation of the NHE3 gene
could be responsible, at least in part, for the observed increase of
NHE3 activity and expression in response to chronic exposure to
Ang II. This regulation involves the Sp1/Egr-1 DNA binding site
and activation of several AT1R-dependent signaling pathways,
whose interplay ends in up-regulation of transcription. The abil-
ity of Ang II to modulate gene expression in situations of chronic
stimuli may be an important mechanism in the regulation of Na+
and ﬂuid reabsorption in proximal tubules.
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